tam2002 said:
What's everyone's thoughts on ELOX here?
ELOX-02 showed sweat chloride reduction of 5.4mmol/L, which was a key secondary outcome measure. This was seen on 12 patients that took upto the 1.5 mg/kg dose. No increase in FEV1 which was the second secondary endpoint (this was expected). Primary endpoin was safety and the results showed that delivery by injection was safe.
They want to expand the trial to the 1.5 mg/kg dose in combination with ivacaftor (one of the drugs involved in Vertex's trikafta). They think this will result in even better. Note ivacaftor doesn't do anytthing for class 1 CF patients.
10-12k patients in CF Class 1 patients at a pricepoint similar to Trikafta (Vertex) = 1.5-3.0 bln revenue per year is what was mentioned on the call I believe....
They will submit data for combination therapy Ph 2 trial by end of 1H 2022
Submit IND for inhaled ELX-02 2H 2022 and end phase 2 meeting for injectionversion with FDA.
Honestly from a stock perspective, not sure where this goes from here. Thought this was on target yet the stock is selling off and will be <1 soon.